SP ~ $34 (2019) - ~$15 (2024)
- The longterm CEO is the 2nd largest shareholder with, imo, an inappropriate compensation package for a public company of its size?
- The Board comprises directors with, imo, questionable independence & experience and one cannot imagine they are providing sufficient independent challenge to the executive management team?
- The CEO should take this lifestyle Company private rather than continue to fool himself and others that it is being run as an independent public company in the interest of ALL shareholders. PE would not tolerate the cost base, profligacy and performance
- Time for a change?
- Forums
- ASX - By Stock
- Time for a Change
CUV
clinuvel pharmaceuticals limited
Add to My Watchlist
5.34%
!
$11.84

SP ~ $34 (2019) - ~$15 (2024)- The longterm CEO is the 2nd...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$11.84 |
Change
0.600(5.34%) |
Mkt cap ! $593.4M |
Open | High | Low | Value | Volume |
$11.24 | $12.13 | $11.23 | $3.118M | 263.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3971 | $11.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.95 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3971 | 11.800 |
2 | 1090 | 11.780 |
4 | 6848 | 11.750 |
1 | 854 | 11.710 |
1 | 619 | 11.700 |
Price($) | Vol. | No. |
---|---|---|
11.950 | 2000 | 1 |
12.000 | 10300 | 2 |
12.080 | 5000 | 1 |
12.120 | 200 | 1 |
12.130 | 600 | 1 |
Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |